title: The efficacy of high-dose 4'epidoxorubicin in hepatocellular carcinoma.
abstract: An open phase II study of high-dose 4'epidoxorubicin (90 mg/m2) was conducted in 33 patients with inoperable hepatocellular carcinoma. Three out of the 33 (9%) patients showed tumour response. The treatment was relatively well tolerated with a moderate degree of haematological toxicity and alopecia, and a mild degree of nausea and vomiting. The overall median survival was 72 days with a prolongation in the patients who showed some response.
authors.affiliation: Department of Clinical Oncology, Chinese University of Hong Kong, Shatin.
authors.forename: W
authors.initials: W
authors.lastname: Shiu
authors.forename: N
authors.initials: N
authors.lastname: Leung
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: W T
authors.initials: WT
authors.lastname: Leung
authors.forename: A K
authors.initials: AK
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D015251:Epirubicin; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D015251:Epirubicin; D004317:Doxorubicin